Loading stock data…
Generate Biomedicines, Inc. (GENB)
$16.91+0.44 (+2.67%)
Market ClosedLast close Jun 29
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $7.22M↓ | $8.82M |
| Gross Profit | — | — |
| Operating Income | -$64.11M↓ | -$48.15M |
| Net Income | -$61.45M↓ | -$41.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.03%
Volume
Today's trading volume
1.70M
Recent News
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]
A Look At Generate Biomedicines (GENB) Valuation As Shares Soften After Recent Gains
Recent trading snapshot and business context Generate Biomedicines (GENB) has drawn investor interest after a mixed stretch in the stock, with a small gain of 0.2% over the past day set against a decline of 9.7% over the past week. Over the past month the stock is roughly flat, while the past 3 months show a gain of 10.0%. This recent trading context sits alongside a market value of about US$1.68b and a share price of US$13.12 at the last close. See our latest analysis for Generate...
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.
A Deep Dive Into NVIDIA’s Latest Portfolio Moves
NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into […]